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Pancreatic carcinoma is one common cancer with gradually increasing incidence during the past several decades. However,
currently the candidate drugs to suppress pancreatic cancer remain lacking. This research was carried out to investigate if
zerumbone,anaturalcyclicsesquiterpeneisolatedfromZingiberzerumbetSmith,willproducetheanticancereﬀectsonpancreatic
carcinoma cell lines. The resultsshowed that zerumbone concentration, andtime, dependently produced inhibitoryactions oncell
viability of PANC-1 cells. In addition, Hoechst 33342, AO/EB, TUNEL staining, and caspase-3 activity assay further showed that
zerumboneinducedapoptosisofPANC-1cells.Theexpressionofp53proteinwasmarkedlyupregulated,andthep21levelwasalso
obviously elevated in zerumbone-treated PANC-1 cells. Moreover, ROS production was increased by about 149% in PANC-1 cells
treated by zerumbone 30μM. Zerumbone also produced the same antitumor activity in pancreatic carcinoma cell lines SW1990
and AsPC-1. In summary, we found that zerumbone was able to induce apoptosis of pancreatic carcinoma cell lines, indicating to
be a promising treatment for pancreatic cancer.
1.Introduction
As a crucial part of the digestive system, the incidence of
pancreatic cancer is gradually increasing during the past dec-
ades all over the world. It was reported that approximately
37,000 individuals were diagnosed with pancreatic cancer in
the United States [1] .T h e5 - y e a rs u r v i v a lr a t eo fp a t i e n t s
with pancreatic cancer is less than 10%, and more than
30,000 people die from this cancer every year [2]. Pancreatic
cancer remains one of the four or ﬁve most common causes
of cancer mortality in developed countries. Currently, the
therapeutic drugs for pancreatic cancers are lacking, and
were hampered by their toxic actions on normal organs.
Particularly,pancreaticcancerisseldomdiagnosedduringits
early stages in clinics [2, 3]. Accordingly, developing the new
drug and strategy to prevent or treat pancreatic cancer is an
important mission.
Zingiber zerumbet Smith is one kind of plant growing
mainly in Southeast Asia, which has been demonstrated to
possess antinociceptive, anti-inﬂammatory, antiulcer, anti-
hyperglycemic, and antiplatelet activities [4–7]. As a major
compound extract, zerumbone is currently explored for its
potential broad use on cancers, leukemia, as well as virus
infection (Figure 1)[ 8–10]. Recently, several studies have
shown that zerumbone also produced a variety of phar-
macological eﬀects, including antioxidants, antivirus, anti-
inﬂammatory, hepatoprotection, antiplatelet aggregation,
and antibacterial [8–13]. Recently, the increasing attention
was paid to the anticancer actions of zerumbone. It was
reported that zerumbone exhibited a strong ability to treat
liver cancer, lung carcinogenesis, and leukemia through
increasing the apoptosis and inhibiting the invasion [8, 12–
15]. But, whether zerumbone played the inhibitory roles in
pancreatic cancer cells remains unknown. The present study2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: The chemical structure of zerumbone, a Southeast Asian
ginger sesquiterpene.
was undergone aiming to determine the antitumor role of
zerumbone in pancreatic cancers.
2.MaterialsandMethods
2.1. Cell Culture. Human pancreatic carcinoma cell lines
PANC-1 and SW1990 were cultured in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) containing penicillin (100
units/mL), streptomycin (100μg/mL), and L-glutamine
(300μg/mL) supplemented with 10% fetal bovine serum
(FBS). AsPC-1 cells were cultured in RPMI-1640 medium
supplementedwith10%FBS.Thecultureconditionforthese
cell lines was at 37◦C in a humidiﬁed atmosphere of 5%
CO2 and 95% air in a plastic ﬂask. All cultured medium was
changed twice every week.
2.2. Reagents. Zerumbone, DMSO, MTT (3-(4,5-Dimeth-
ylthiazol-2-yl)-2,5-Diphenyl Tetrazolium Bromide) kit, and
other reagents, if not otherwise speciﬁed, were purchased
from Sigma-Aldrich, St. Louis, MO, USA. Hoechst 33342
dye and Trizol were obtained from Invitrogen, Carlsbad, CA.
In Situ Cell Death Detection Kit was bought from Roche,
Penzberg, Germany (Catalog no. 11684795910). Caspase-3
activity colorimetric kit was purchased from R&D Systems
Inc. (Biovision, Mountain View, USA). PA Lysis Buﬀer was
obtained from Beyotime, Shanghai. The p53, p21 mono-
clonal, and PUMA polyclonal antibody were bought from
Santa Cruz Biotechnology (Santa Cruz, CA). RNeasy Mini
Kit and RNase-free DNase Set were obtained from Qiagen,
Valencia, CA. TaqMan Reverse Transcription Reagents were
purchased from Applied Biosystems, Foster City, CA. For
all experiments of this study, DMSO was used to dissolve
zerumbone. In order to avoid possible eﬀects to these cells
by DMSO, the volume of DMSO should not exceed 0.1% of
the total volume (v/v).
2.3. Cell Proliferation Assay. The cellular viability of pan-
creatic cancer cells was determined by MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyl Tetrazolium Bromide)
assay. Brieﬂy, the cells were collected and seeded in 96-well
plates to attach overnight in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). Human pancreatic cancer cells were rendered
quiescent by incubation in serum-free media for 24h. Then
pancreaticcancercellswereincubatedwithzerumbone3,10,
30, and 100μM for 24h or were cultured for 24, 48, and
72h in the presence of 30μM, respectively. Then, the culture
media were washed out and the fresh media containing
5 m g / m LM T Tw e r ea d d e d .T h ec e l l sw e r ec o n t i n u o u s l y
incubated at 37◦C for an additional four hours. After this
time, the media were washed out, and reduced MTT product
(blue formazan product) was solubilized by adding 100μM
DMSO to each wells. After agitation of these plates for
15min, the optical density of the solubilized formazan
product in each well was measured using a microplate reader
at 570nm with background subtraction at 650nm. The
experiment to observe diﬀerent concentration of zerumbone
on cellular viability of pancreatic cancer cells was carried out
six times, and the experiment to study diﬀerent incubation
times of zerumbone on cellular viability was performed ﬁve
times.
2.4. Acridine Orange/Ethidium Bromide (AO/EB) Staining.
Morphological signs of apoptosis were detected by using
acridine orange-ethidium bromide (AO/EB) staining in pan-
creaticcancercells.Thecellswereincubatedwithzerumbone
for 24h. The procedure to perform AO/EB staining is just
as described below. In order to staining the apoptotic cells,
10μL prepared AO/EB working solution (100μg/mL AO and
100μg/mL EB in PBS) was added to each well for 5min.
Then the pancreatic cancer cells were harvested and the
apoptotic cells were counted under an inverted ﬂuorescence
microscope (Eclipse TE300, Nikon, Japan).
2.5. Hoechst 33342 Dye Staining. Morphological changes of
apoptotic pancreatic cancer cells were evaluated by Hoechst
33342 staining. In brief, the cultured cells were planted in
6-well plates and then exposed to zerumbone treatment
for 24h. After being washed with PBS, the cancer cells
were ﬁxed in 4% paraformaldehyde for 30min at room
temperature. After being washed again with PBS, the ﬁxed
cellswerestainedwith20μg/mLHoechst33342for15minat
room temperature. The cells were imaged with ﬂuorescence
microscope.
2.6. Terminal Deoxynucleotidyl Transferase-Mediated dUTP
Nick End Labeling (TUNEL) Assay. TUNEL assay was used
to identify the apoptosis of pancreatic cancer cells. The cells
were seeded in dishes, grown overnight, and subjected to
zerumbone 3, 10, 30, and 100μM for 24h. The staining
of apoptotic cells was carried out using an In Situ Cell
Death Detection Kit. In brief, after being washed twice with
PBS, human pancreatic cancer cells were then ﬁxed with
4% paraformaldehyde in PBS (pH 7.4) for 1h at room
temperature. The ﬁxed cancer cells were permeabilised by
incubation with 0.1% Triton X-100 in 0.1% sodium citrate
for 2min on ice. The cells were rinsed again with PBS and
incubated with TUNEL reaction mixture for 1h at 37◦C
in the dark. TUNEL staining of apoptotic cells was viewed
under a ﬂuorescence microscopy (Olympus, Tokyo, Japan).
2.7. Measurement of Reactive Oxygen Species (ROS). To
quantify intracellular ROS level, we used 2,7-dichlorodihy-
droﬂuorescein diacetate (H2DCF-DA) probe. The procedureEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: Eﬀects of zerumbone on the cellular viability of PANC-1 cells. (a) The cellular viability of PANC-1 was signiﬁcantly reduced by
zerumbone 3, 10, 30, and 100μM after 24h incubation. n = 6 independent experiments. (b) Zerumbone obviously decreased the cellular
viability of PANC-1 cells in a time-dependent manner. n = 5 independent experiments,
∗P < 0.05 versus Control.
forROSmeasurementisaspreviouslydescribed[16].Brieﬂy,
the cells were seeded and then were incubated with diﬀerent
concentration of zerumbone for 24h. In order to detect
the production of ROS, the pancreatic cancer cells were
collected, washed twice with PBS, and loaded with H2DCF-
DA 10 μM by incubation for 30min at 37◦C. Fluorescence
was measured by ﬂow cytometry. The experiment with ROS
assay was repeated four times.
2.8. Caspase-3 Activity Assay. To evaluate the caspase-3
activity, the cancer cells lysates were prepared after their
respective treatment with zerumbone. The caspase-3 activity
was determined by colorimetric kit. Then, assays were per-
formed by incubating 20mg of cell lysates with 200mM
chromogenic substrate (DEVD-pNA) in 100mL reaction
buﬀer. The cell lysate was incubated at 37◦Cf o r2 h .
Thereafter, the absorbance at 450nm was measured to
represent the release of chromophore p-nitroanilide (pNA).
The experiment with caspase-3 assay was repeated three
times.
2.9. Western Blot Analysis. For immunolabeling, the lysates
were prepared after the cancer cells were subjected to
their respective treatment with zerumbone. One hundred
micrograms of each lysate were resolved by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE).
After electrophoresis, the proteins were transferred onto a
nitrocellulose membrane. After blocking with 5% nonfat
dried milk and 0.05% Tween 20 in Tris-buﬀered saline
(10mM Tris, pH 8.0, 135mM NaCl), the membranes were
incubated overnight with the relevant primary antibody
followed by the incubation with horseradish peroxidase-
conjugated immunoglobulin G (IgG). The blots were then
visualized by using Odyssey v1.2 software. The experiments
were repeated three times.
2.10. Quantitative Real-Time PCR Analysis. According to
the guideline of the manufacturer, the total RNA from
pancreatic cancer cells was isolated by Trizol and puriﬁed by
RNeasy Mini Kit and RNase-free DNase Set. Total RNA from
pancreatic cancer cells was subjected to ﬁrst-strand cDNA
synthesis using TaqMan Reverse Transcription Reagents. The
method to determine miR-34 mRNA level in cancer cells is
just as described previously [17]. Relative mRNA for miR-
34 was calculated by the comparative CT method (DDCT)
using U6 as an endogenous control and untreated samples as
the calibrator.
2.11. Statistical Analysis. All data was presented as mean ±
S.E.M. Statistical analysis was performed to determine the
signiﬁcance of diﬀerences among groups using ANOVA.
All statistical analysis was performed using the SPSS 13.0
software for Windows. Statistical signiﬁcance was initially set
at P<0.05.
3. Results
3.1. Zerumbone Reduced Cellular Viability of PANC-1 Cells.
The eﬀects of zerumbone on the proliferation of PANC-
1 cells were measured by the MTT assay. As displayed in
Figure 2(a), the exposure of PANC-1 cells to zerumbone
3μM, 10μM, 30μM, and 100μMf o r2 4 hr e s u l t e di na
signiﬁcant reduction of cellular viability, compared with
untreated cells (P<0.05). Zerumbone 3μM, 10μM, 30μM,
and 100μM decreased the viability of PANC-1 cells from
97.9±5.3t o7 8 .2±6.4, 70.1±6.0, 55.6±7.2, and 49.1±8.1,
respectively, (P<0.05). Figure 2(b) showed that cellular
viability of PANC-1 cells after exposure to zerumbone 30μM
f o r2 4 h ,4 8 h ,a n d7 2 hw a sd e c r e a s e df r o m9 5 .3 ± 3.8t o
57.8 ± 6.2, 47.4 ± 7.5, and 33.6 ± 7.9. The results suggest4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of zerumbone on apoptosis of PANC-1 cells. (a) Hoechst 33342 staining of the apoptosis of PANC-1 in the presence of
zerumbone 30μM. (b) Eﬀects of zerumbone 30μM on apoptosis of PANC-1 cells were identiﬁed by AO/EB staining. (c) and (d) TUNEL-
positive cells were viewed in the presence of zerumbone 30μM. n = 3 independent experiments,
∗P < 0.05 versus Control.
that zerumbone reduces the proliferation of PANC-1 in a
concentration- and time-dependent manner (P<0.05).
3.2. Apoptosis of PANC-1 Cells Was Induced by Exposure to
Zerumbone. We further used Hoechst 33342 and AO/EB
staining to determine the eﬀects of zerumbone on the apop-
tosis of PANC-1 cells. As demonstrated in Figures 3(a) and
3(b), zerumbone-treated PANC-1 cells exhibited obvious
apoptotic morphological changes in the nuclear chromatin,
such as cell shrinkage, chromatin condensation, and cell
nuclear fragmentation. By contrast, PANC-1 cells without
zerumbone treatment presented the intact nuclear architec-
ture (Figure 3(b)). As shown in Figure 3(c), TUNEL-positive
stainingcouldbedetectedmoresigniﬁcantlyinPANC-1cells
pretreated by zerumbone than in untreated PANC-1 cells.
Zerumbone 3μM, 10μM, 30μM, and 100μM signiﬁcantly
increased the number of TUNEL-positive PANC-1 cells from
7.1±1.9% to 21.3±3.6, 33.8±4.0, 47.1±6.6a n d5 2 .3±5.9
after 24h incubation (P<0.05).
3.3. Zerumbone Increased the Activity of Caspase-3 and ROS
in PNAC-1 Cells. The eﬀect of zerumbone on the activity
of caspase-3 in PANC-1 cells was further investigated. As
illuminated in Figure 4(a), the exposure of PANC-1 cells
to zerumbone 3μM, 10μM, 30μM, and 100μMm a r k e d l y
increased the activity of caspase-3 by approximately 56%,
147%, 149%, and 197%, respectively, (P<0.05). These
results further conﬁrmed that zerumbone induced apop-
tosis of PANC-1 cells. Then, we explored the inﬂuences
of zerumbone on the production of ROS. PANC-1 cells
were exposed to zerumbone 3μM, 10μM, 30μM, and
100μM for 24h and analyzed for the production of ROS
by ﬂuorescence microscopy. Figure 4(b) demonstrated the
ﬂuorescence image of ROS in the absence and presence
of zerumbone in PANC-1 cells. The generation of ROS
was increased by zerumbone in a concentration-dependent
manner (P<0.05).
3.4. Eﬀects of Zerumbone on the Expression of p53 and
miR-34. We further investigate whether zerumbone plays
a regulatory role in the expression of p53 and miR-34.
As displayed in Figure 5(a), pretreatment with zerumbone
30μM signiﬁcantly increased the expression of p53 protein
in PANC-1 cells (P<0.05). In agreement, miR-34 level
was also augmented in zerumbone-treated PANC-1 cells
(P<0.05) (Figure 5(b)). These results imply that p53
signal pathway is involved in the apoptosis of PANC-
1 cells induced by zerumbone. Moreover, the eﬀects of
zerumbone on p21 and PUMA protein were investigated
and the results showed that PUMA was not aﬀected but p21
was signiﬁcantly upregulated, indicating that p53 and p21
signalpathwaywasactivatedaftertreatmentwithzerumboneEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Eﬀects of zerumbone on the caspase-3 activity and the generation of ROS production of PNAC-1 cells. (a) Zerumbone increased
the caspase-3 activity of PANC-1 cells. n = 3 independent experiments. (b) Zerumbone 30μM increased the ﬂuorescence density of ROS.
ZerumboneincreasedtheROSgenerationinaconcentration-dependentmanner.n = 4independentexperiments,
∗P < 0.05versusControl.
(Figure 5(a))( P<0.05). We further investigate the eﬀects of
thep53-speciﬁcinhibitorpiﬁthrin-αonzerumbone-induced
decrease of cellular viability in PANC-1 (Figure 5(c)). The
results showed that piﬁthrin-α 20μM reversed the inhibitory
role of zerumbone 30μM in cellular viability of PANC-1,
indicating that zerumbone exerts antitumor eﬀects through
p53-dependent manner.
3.5. Zerumbone Induced Apoptosis in SW1990 and AsPC-1
Cells. Wealsostudiedtheantitumoreﬀectsofzerumboneon
another two pancreatic cancer cell lines SW1990 and AsPC-
1. Figures 6(a) and 6(b) showed that zerumbone 30μM
markedly inhibited cellular viability of SW1990 and AsPC-
1 after 24h incubation (P<0.05). Furthermore, Hoechst
33342 staining displayed that the exposure to zerumbone
30μM for 24h induced obvious apoptotic morphological
changes in the nuclear chromatin in SW1990 and AsPC-1
(Figure 6(c)). Figures 6(d) and 6(e) showed that zerumbone
30μM increased the caspase-3 activity in both SW1990
and AsPC-1. These ﬁndings suggest the antitumor role of
zerumbone in SW1990 and AsPC-1 cell lines.
4. Discussion
It was demonstrated in this study that exposure to zerum-
bone resulted in apoptosis of PANC-1 cells through p53
signal pathway. The present research oﬀe r su san e wu n d e r -
standing about the molecular mechanisms of antitumor
actions of zerumbone on pancreatic cancer.
A large body of evidence demonstrated that apoptosis
is a normal component of the development and health of
multicellular organisms and also is a key way to clear the
unnecessary cells [18, 19]. Notably, apoptosis is more im-
portant in understanding cancer, because cancer cells have
developedawaytoavoidapoptosis[20].Thus,cancerisoften
characterized by too little apoptosis and too much prolifera-
tion of cells. To promote apoptosis and inhibit proliferation
of cancer cells has been suggested as a therapeutic approach.
Zerumboneisasesquiterpenephytochemicalfromatype
of edible ginger known as “Zingiber zerumbet Smith” grown
in Southeast Asia or “Zingiber aromaticum” [4–9]. In several
studies, zerumbone has been showed to play an antitumor
role in liver cancer, leukemia, and lung carcinogenesis,
which was considered as a promising therapeutic drug for
cancers [8–15]. For example, zerumbone was reported to
induce G2/M cell cycle arrest and apoptosis in leukemia
cells through a Fas- and mitochondria-mediated pathway
[12]. In addition, zerumbone also could eﬀectively suppress
mouse colon and lung carcinogenesis through multiple
modulatory mechanisms of growth, apoptosis, inﬂamma-
tion, and expression of NFkappaB and HO-1 after dietary
administration [13]. Zerumbone was shown to strongly
inhibit the proliferation of liver cancer cells and enhance
the apoptosis [15]. However, the information about the
therapeutic eﬀects of zerumbone on pancreatic cancer cells
is unavailable. In this study, we uncover for the ﬁrst time
that zerumbone-treated pancreatic cancer cells exhibited a
decreased proliferation and increased apoptosis, which is
characterized by the formation of apoptotic bodies, con-
densed nuclei, and the increased activity of caspase-3. The
present study therefore oﬀered a new possible application of
zerumbone in the treatment of pancreatic cancer.
It is well documented that p53 plays an important role
in the control of cell cycle and apoptosis [20]. As a tumor
suppressor,p53playsamorecrucialroleinpreventingtumor
development [21]. It is considered responsible for a range
of potentially oncogenic stresses by activating antitumor
mechanisms, most notably cell cycle arrest and apoptosis.
The present study displayed that p53 was signiﬁcantly
increased in zerumbone-treated PANC-1 cells. It suggests6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀects of zerumbone on the expression of p53 and miR-34. (a) Zerumbone 30μM markedly inhibited the p53, p21, and PUMA
protein expression. (b) Zerumbone 30μM decreased the miR-34 level. (c) The p53 speciﬁc inhibitor piﬁthrin α reversed the inhibitory
inﬂuences of zerumbone on cellular viability. n = 3 independent experiments,
∗P < 0.05 versus Control, #P < 0.05 versus Zerumbone.
that p53 may contribute to the inhibition of the apoptosis
of pancreatic cancer cells by zerumbone.
A new component of p53 signaling pathway was recently
uncovered, and it was showed that the activation of endoge-
nous p53 induced the upregulation of miR-34 expression
and p21, suggesting that miR-34 is a direct target of p53
[22]. Furthermore, it was previously reported that the
overexpression of miR-34a led to the growth arrest and
apoptosis in neuroblastoma cells by silencing the expression
of E2f3 [23]. We found that miR-34 and p21 were obviously
increased in zerumbone-treated PANC-1 cells, indicating
that p53 signal pathway is activated by zerumbone.
Reactive oxygen species (ROS) are a variety of molecules
and free radicals derived from molecular oxygen, which was
constantly generated and eliminated in the biological system,
and have important roles in cell signaling and homeostasis
[24]. Excessive amounts of ROS can cause oxidative damage
to lipids, proteins, and DNA leading to tumorigenesis or
cell death. Although the use of antioxidants in humans for
cancer prevention remains controversial, increasing evidence
supported that the increase of ROS generation contributed
to the treatment of cancer cells. Reactive oxygen species
are suggested as downstream mediators of p53-dependent
apoptosis [25, 26]. The cells sensitive to p53-mediated
apoptosis promoted the generation of ROS, whereas cells
resistant to p53 failed to produce ROS [25]. We found that
zerumbone exerted a facilitated role in the production of
ROS in a concentration-dependent manner, which is at least
inpartresponsibleforitspharmacologicalactionsonPANC-
1 cell lines.Evidence-Based Complementary and Alternative Medicine 7
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Figure 6: Zerumbone induced apoptosis in SW1990 and AsPC-1 cells. (a) Zerumbone 30μM signiﬁcantly decreased the cellular viability
of SW1990 after 24h incubation. (b) The cell viability of AsPC-1 cells was also strongly inhibited in the present of Zerumbone 30μM. (c)
Hoechst 33342 staining of SW1990 and AsPC-1 cells in the absence and presence of zerumbone 30μM. (d) Zerumbone 30μM increased
the caspase-3 activity in SW1990 cells. (e) Zerumbone 30μM also enhanced the caspase-3 activity in AsPC-1 cells. n = 3 independent
experiments, ∗P<0.05 versus Control.8 Evidence-Based Complementary and Alternative Medicine
In summary, it was uncovered in our study that
zerumbone induced apoptosis in pancreatic carcinoma
cells through p53 signal pathway. This ﬁnding indicates
zerumbone, a sesquiterpene in subtropical ginger, as a new
therapeutic candidate for pancreatic cancer.
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